查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1709481

免疫檢查點抑制劑市場，按類型、按給藥途徑、按分佈、按應用、按最終用戶、按國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Immune Checkpoint Inhibitors Market, By Type, By Route of Administration, By Distribution, By Application, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 322 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

免疫檢查點抑制劑市場規模在 2024 年價值 489.839 億美元，從 2025 年到 2032 年的複合年成長率為 17.60%。

免疫檢查點抑制劑市場-市場動態

癌症盛行率的上升和監管部門的批准加速了市場的成長

癌症盛行率的上升和監管部門批准的增加正在加速免疫檢查點抑制劑市場的成長。根據世界衛生組織 (WHO) 統計，全球新增癌症病例超過 1,900 萬例，推動了對先進免疫療法的需求。美國 FDA 已批准多種檢查點抑制劑，包括 pembrolizumab（Keytruda）和 nivolumab（Opdivo），用於治療肺癌、黑色素瘤和大腸癌。美國國家癌症研究所 (NCI) 報告稱，涉及檢查點抑制劑的聯合療法在臨床試驗中已顯示出提高的存活率，這有助於其採用率的提高。此外，政府和研究機構正在大力投資免疫腫瘤學，目前有超過 4,000 項臨床試驗正在進行中。然而，由於成本高昂，取得藥物仍然是一個挑戰，因此需要增加生物相似藥的開發和價格談判。隨著批准範圍的擴大和研究的進展，市場將進一步融入標準癌症治療。

免疫檢查點抑制劑市場—關鍵見解

根據我們的研究分析師的分析，預測期內（2025-2032 年）全球市場預計年複合成長率約為 17.60%

根據類型細分，預計 PD-1 抑制劑將在 2024 年佔據最大市場佔有率

根據給藥途徑細分，腸外給藥是 2024 年最主要的給藥途徑

根據分銷細分，醫院藥局是 2024 年的主要分銷管道

根據應用細分，肺癌是 2024 年的主要應用

根據最終用戶細分，醫院和診所是 2024 年領先的最終用戶

按地區分類，北美是 2024 年的主要收入來源

免疫檢查點抑制劑市場-細分分析：

全球免疫檢查點抑制劑市場根據類型、給藥途徑、分佈、應用、最終用戶和地區進行細分。

市場依類型分為三類：PD-1 抑制劑、PD-L1 抑制劑和 CTLA-4 抑制劑。 PD-1 抑制劑因其在多種癌症類型中獲得廣泛批准且具有強大的臨床療效而佔據市場主導地位。 PD-L1 抑制劑緊隨其後，在聯合療法中越來越受到關注。 CTLA-4 抑制劑所佔佔有率較小，但在特定癌症治療中仍然至關重要。

根據給藥途徑，市場分為兩類：口服和腸外給藥。腸外給藥引領市場，因為大多數免疫檢查點抑制劑都是透過靜脈輸注來達到最佳療效。口服製劑正在出現但仍然有限。其他方法，包括新穎的交付方法，在不斷改進管理技術的研究下佔據了一定佔有率。

免疫檢查點抑制劑市場—地理洞察

免疫檢查點抑制劑市場正在全球擴張，其中北美由於強大的研究資金、先進的醫療保健基礎設施和免疫療法的廣泛採用而處於領先地位。美國 FDA 已批准多種檢查點抑制劑，默克、百時美施貴寶和羅氏等主要參與者正在推動創新。歐洲緊隨其後，得到歐洲藥品管理局 (EMA) 等組織日益增多的監管批准和舉措的支持，以增強癌症治療的可及性。亞太地區正在經歷快速成長，中國和日本大力投資免疫腫瘤學研究和國內藥物開發。中國國家藥品監督管理局（NMPA）加快了核准速度，促進了本地競爭。在拉丁美洲，醫療保健服務的改善和癌症發病率的上升正在增加需求，但負擔能力仍然是一項挑戰。在不斷擴大的臨床試驗和國際合作的推動下，中東和非洲正在經歷緩慢但穩定的採用，為該地區未來的市場滲透奠定了基礎。

免疫檢查點抑制劑市場-競爭格局：

免疫檢查點抑制劑市場競爭激烈，各大製藥公司透過廣泛的研發、策略合作和監管部門批准推動創新。默克公司（Keytruda）和百時美施貴寶（Opdivo、Yervoy）憑藉強大的臨床試驗管道和不斷擴大的適應症引領市場。羅氏（Tecentriq）、阿斯特捷利康（Imfinzi）和輝瑞（Bavencio）也是主要參與者，專注於聯合療法以提高療效。新興生物技術公司和亞洲製藥公司（如百濟神州和信達生物）正在透過開發具有成本效益的替代品並擴展到全球市場來加劇競爭。默克與 Moderna 公司在個人化癌症疫苗方面的合作等策略夥伴關係正在進一步塑造這一格局。目前有超過 4,000 項臨床試驗正在進行中，各公司正在積極探索 LAG-3、TIGIT 和 TIM-3 的下一代檢查點抑制劑。定價壓力和生物相似藥的發展預計將重塑競爭，使可負擔性和可及性成為市場擴張的關鍵因素。

最新動態：

2024 年 12 月，Checkpoint Therapeutics 宣布 FDA 批准 UNLOXCYT(TM) (cosibelimab-ipdl)，這是首個用於治療晚期皮膚鱗狀細胞癌 (cSCC) 的抗 PD-L1 療法。這是 Checkpoint 首次獲得市場批准，為無法接受手術或放射治療的患者提供差異化治療選擇，有可能改善治療效果。

2024 年 9 月，OmRx Oncology 啟動 OX-4224 的研發，這是一款針對 PD-1/PD-L1 路徑的在研口服檢查點抑制劑。為了增加全球範圍內獲得癌症免疫療法的機會，OmRx 將首先在中低收入國家研究 OX-4224 作為單一療法，首先在印度針對 NSCLC 進行 2 期試驗。

目錄

第1章：免疫檢查點抑制劑市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 免疫檢查點抑制劑市場片段（按類型）
    • 免疫檢查點抑制劑市場片段（依給藥途徑）
    • 免疫檢查點抑制劑市場片段（依分佈）
    • 免疫檢查點抑制劑市場片段（依應用）
    • 免疫檢查點抑制劑市場片段（按最終用戶）
    • 免疫檢查點抑制劑市場（按國家/地區）
    • 免疫檢查點抑制劑市場（按地區）
  • 競爭洞察

第3章：免疫檢查點抑制劑主要市場趨勢

  • 免疫檢查點抑制劑市場促進因素
    • 市場促進因素的影響分析
  • 免疫檢查點抑制劑市場限制
    • 市場限制的影響分析
  • 免疫檢查點抑制劑的市場機遇
  • 免疫檢查點抑制劑市場未來趨勢

第4章：免疫檢查點抑制劑產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：免疫檢查點抑制劑市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：免疫檢查點抑制劑市場格局

  • 免疫檢查點抑制劑市場佔有率分析（2024年）
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：免疫檢查點抑制劑市場－依類型

  • 概述
    • 按類型分類的細分市場佔有率分析
    • PD-1抑制劑
    • PD-L1抑制劑
    • CTLA-4抑制劑
    • 其他

第 8 章：免疫檢查點抑制劑市場 - 按給藥途徑

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 口服
    • 腸外
    • 其他

第9章：免疫檢查點抑制劑市場－依分佈

  • 概述
    • 按分佈細分市場佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第 10 章：免疫檢查點抑制劑市場 - 按應用

  • 概述
    • 按應用細分市場佔有率分析
    • 肺癌
    • 乳癌
    • 膀胱癌
    • 黑色素瘤
    • 子宮頸癌
    • 霍奇金淋巴瘤
    • 大腸直腸癌
    • 其他

第 11 章：免疫檢查點抑制劑市場 - 按最終用戶

  • 概述
    • 按最終用戶細分的佔有率分析
    • 醫院和診所
    • 癌症中心
    • 學術和研究機構

第 12 章：免疫檢查點抑制劑市場 - 按地區

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美免疫檢查點抑制劑主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模和預測（按類型）
    • 北美市場規模及預測（按給藥途徑）
    • 北美市場規模和預測（按分佈）
    • 北美市場規模和預測（按應用）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲免疫檢查點抑制劑主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模與預測（按類型）
    • 歐洲市場規模及預測（依管理途徑）
    • 歐洲市場規模及預測（按分佈）
    • 歐洲市場規模和預測，按應用
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區免疫檢查點抑制劑主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（按類型）
    • 亞太地區市場規模及預測（依管理途徑）
    • 亞太地區市場規模及預測（依分佈）
    • 亞太地區市場規模及預測（按應用）
    • 亞太地區市場規模及預測（依最終用戶）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲免疫檢查點抑制劑主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（按類型）
    • 拉丁美洲市場規模及預測（依管理途徑）
    • 拉丁美洲市場規模及預測（依分佈）
    • 拉丁美洲市場規模及預測（按應用）
    • LATAM 規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲免疫檢查點抑制劑主要製造商
    • 中東和非洲市場規模及預測（按國家/地區）
    • 中東和非洲市場規模和預測（按類型）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（按分佈）
    • 中東和非洲市場規模和預測（按應用）
    • 中東和非洲市場規模及預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 13 章：免疫檢查點抑制劑產業關鍵供應商分析

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • AstraZeneca plc
    • BeiGene, Ltd.
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Incyte Corporation
    • Innovent Biologics, Inc.
    • Jiangsu Hengrui Medicine Co., Ltd.
    • Merck & Co., Inc.
    • Novartis International AG
    • Pfizer Inc.
    • Regeneron Pharmaceuticals, Inc.
    • Sanofi SA
    • Shanghai Junshi Biosciences Co., Ltd.
    • Tesaro, Inc.
    • Others

第 14 章：360 度分析師視角

第 15 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4954

REPORT HIGHLIGHT

Immune Checkpoint Inhibitors Market size was valued at US$ 48,983.90 Million in 2024, expanding at a CAGR of 17.60% from 2025 to 2032.

The Immune Checkpoint Inhibitors Market focuses on therapies that block checkpoint proteins like PD-1, PD-L1, and CTLA-4 to enhance the immune system's ability to attack cancer cells. Growing cancer prevalence, with over 19 million new cases reported globally in recent years, has accelerated demand for these therapies. Expanding FDA approvals for drugs like pembrolizumab (Keytruda) and nivolumab (Opdivo) across multiple cancer types further fuel market expansion. However, high treatment costs, with some therapies exceeding $150,000 annually per patient, and immune-related adverse effects pose challenges. Ongoing research into combination therapies and novel checkpoint targets presents significant growth opportunities, with clinical trials increasing by nearly 40% over the past five years. Emerging biopharma players and strategic collaborations are further strengthening innovation in this rapidly evolving sector.

Immune Checkpoint Inhibitors Market- Market Dynamics

Expanding cancer prevalence and regulatory approvals accelerating market growth

Expanding cancer prevalence and increasing regulatory approvals are accelerating the growth of the immune checkpoint inhibitors market. According to the World Health Organization (WHO), over 19 million new cancer cases were recorded globally, driving the demand for advanced immunotherapies. The U.S. FDA has approved multiple checkpoint inhibitors, including pembrolizumab (Keytruda) and nivolumab (Opdivo), for treating lung, melanoma, and colorectal cancers. The National Cancer Institute (NCI) reports that combination therapies involving checkpoint inhibitors have shown improved survival rates in clinical trials, contributing to their rising adoption. Additionally, governments and research institutions are investing heavily in immuno-oncology, with over 4,000 clinical trials currently underway. However, access remains a challenge due to high costs, leading to increased efforts in biosimilar development and price negotiations. As approvals expand and research progresses, the market is poised for further integration into standard cancer treatments.

Immune Checkpoint Inhibitors Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 17.60% over the forecast period (2025-2032)

Based on Type segmentation, PD-1 Inhibitors were predicted to show maximum market share in the year 2024

Based on Route of Administration segmentation, Parenteral was the leading Route of Administration in 2024

Based on distribution segmentation, Hospital Pharmacies was the leading distribution in 2024

Based on Application segmentation, Lung Cancer was the leading Application in 2024

Based on end user segmentation, Hospitals & Clinics was the leading end user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Immune Checkpoint Inhibitors Market- Segmentation Analysis:

The Global Immune Checkpoint Inhibitors Market is segmented on the basis of Type, Route of Administration, Distribution, Application, End User, and Region.

The market is divided into three categories based on Type: PD-1 Inhibitors, PD-L1 Inhibitors, and CTLA-4 Inhibitors. PD-1 Inhibitors dominate the market due to their broad approvals across multiple cancer types and strong clinical efficacy. PD-L1 Inhibitors follow, gaining traction in combination therapies. CTLA-4 Inhibitors hold a smaller share but remain crucial in specific cancer treatments.

The market is divided into two categories based on Route of Administration: Oral and Parenteral. Parenteral administration leads the market, as most immune checkpoint inhibitors are delivered via intravenous infusion for optimal efficacy. Oral formulations are emerging but remain limited. Others, including novel delivery methods, hold a niche share with ongoing research into improved administration techniques.

Immune Checkpoint Inhibitors Market- Geographical Insights

The Immune Checkpoint Inhibitors Market is expanding globally, with North America leading due to strong research funding, advanced healthcare infrastructure, and widespread adoption of immunotherapies. The U.S. FDA has approved multiple checkpoint inhibitors, and key players like Merck, Bristol-Myers Squibb, and Roche are driving innovation. Europe follows, supported by increasing regulatory approvals and initiatives from organizations like the European Medicines Agency (EMA) to enhance cancer treatment access. Asia-Pacific is experiencing rapid growth, with China and Japan heavily investing in immuno-oncology research and domestic drug development. China's National Medical Products Administration (NMPA) has accelerated approvals, boosting local competition. In Latin America, improving healthcare access and rising cancer incidence are increasing demand, though affordability remains a challenge. The Middle East and Africa are witnessing slow but steady adoption, driven by expanding clinical trials and international collaborations, positioning the region for future market penetration.

Immune Checkpoint Inhibitors Market- Competitive Landscape:

The Immune Checkpoint Inhibitors Market is highly competitive, with major pharmaceutical companies driving innovation through extensive R&D, strategic collaborations, and regulatory approvals. Merck & Co. (Keytruda) and Bristol-Myers Squibb (Opdivo, Yervoy) lead the market with strong clinical trial pipelines and expanding indications. Roche (Tecentriq), AstraZeneca (Imfinzi), and Pfizer (Bavencio) are also key players, focusing on combination therapies to enhance efficacy. Emerging biotech firms and Asian pharmaceutical companies, such as BeiGene and Innovent Biologics, are intensifying competition by developing cost-effective alternatives and expanding into global markets. Strategic partnerships, like Merck's collaboration with Moderna for personalized cancer vaccines, are further shaping the landscape. With over 4,000 ongoing clinical trials, companies are aggressively exploring next-generation checkpoint inhibitors targeting LAG-3, TIGIT, and TIM-3. Pricing pressures and biosimilar development are expected to reshape competition, making affordability and accessibility critical factors in market expansion.

Recent Developments:

In December 2024, Checkpoint Therapeutics announced FDA approval of UNLOXCYT(TM) (cosibelimab-ipdl), the first anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma (cSCC). This marks Checkpoint's first marketing approval, offering a differentiated treatment option with potential for improved outcomes in patients who cannot undergo surgery or radiation.

In September 2024, OmRx Oncology launched to advance OX-4224, an investigational oral checkpoint inhibitor targeting the PD-1/PD-L1 pathway. Aiming to increase access to cancer immunotherapy worldwide, OmRx will initially study OX-4224 as a monotherapy in low and middle-income countries, starting with a Phase 2 trial in India for NSCLC.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • AstraZeneca plc
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Incyte Corporation
  • Innovent Biologics, Inc.
  • Jiangsu Hengrui Medicine Co., Ltd.
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Sanofi S.A.
  • Shanghai Junshi Biosciences Co., Ltd.
  • Tesaro, Inc.
  • Others

GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • PD-1 Inhibitors
  • PD-L1 Inhibitors
  • CTLA-4 Inhibitors
  • Others

GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Parenteral
  • Others

GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY DISTRIBUTION- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Lung Cancer
  • Breast Cancer
  • Bladder Cancer
  • Melanoma
  • Cervical Cancer
  • Hodgkin Lymphoma
  • Colorectal Cancer
  • Others

GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals & clinics
  • Cancer centers
  • Academic and research institutes

GLOBAL IMMUNE CHECKPOINT INHIBITORS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Immune Checkpoint Inhibitors Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Immune Checkpoint Inhibitors Market Snippet by Type
    • 2.1.2. Immune Checkpoint Inhibitors Market Snippet by Route of Administration
    • 2.1.3. Immune Checkpoint Inhibitors Market Snippet by Distribution
    • 2.1.4. Immune Checkpoint Inhibitors Market Snippet by Application
    • 2.1.5. Immune Checkpoint Inhibitors Market Snippet by End User
    • 2.1.6. Immune Checkpoint Inhibitors Market Snippet by Country
    • 2.1.7. Immune Checkpoint Inhibitors Market Snippet by Region
  • 2.2. Competitive Insights

3. Immune Checkpoint Inhibitors Key Market Trends

  • 3.1. Immune Checkpoint Inhibitors Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Immune Checkpoint Inhibitors Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Immune Checkpoint Inhibitors Market Opportunities
  • 3.4. Immune Checkpoint Inhibitors Market Future Trends

4. Immune Checkpoint Inhibitors Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Immune Checkpoint Inhibitors Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Immune Checkpoint Inhibitors Market Landscape

  • 6.1. Immune Checkpoint Inhibitors Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Immune Checkpoint Inhibitors Market - By Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Type, 2024 & 2032 (%)
    • 7.1.2. PD-1 Inhibitors
    • 7.1.3. PD-L1 Inhibitors
    • 7.1.4. CTLA-4 Inhibitors
    • 7.1.5. Others

8. Immune Checkpoint Inhibitors Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Parenteral
    • 8.1.4. Others

9. Immune Checkpoint Inhibitors Market - By Distribution

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution, 2024 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Online Pharmacies

10. Immune Checkpoint Inhibitors Market - By Application

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 10.1.2. Lung Cancer
    • 10.1.3. Breast Cancer
    • 10.1.4. Bladder Cancer
    • 10.1.5. Melanoma
    • 10.1.6. Cervical Cancer
    • 10.1.7. Hodgkin Lymphoma
    • 10.1.8. Colorectal Cancer
    • 10.1.9. Others

11. Immune Checkpoint Inhibitors Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 11.1.2. Hospitals & clinics
    • 11.1.3. Cancer centers
    • 11.1.4. Academic and research institutes

12. Immune Checkpoint Inhibitors Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Immune Checkpoint Inhibitors Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Immune Checkpoint Inhibitors Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Immune Checkpoint Inhibitors Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Immune Checkpoint Inhibitors Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Immune Checkpoint Inhibitors Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Distribution, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Immune Checkpoint Inhibitors Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. AstraZeneca plc
    • 13.2.2. BeiGene, Ltd.
    • 13.2.3. Bristol-Myers Squibb Company
    • 13.2.4. Eli Lilly and Company
    • 13.2.5. F. Hoffmann-La Roche Ltd.
    • 13.2.6. GlaxoSmithKline plc
    • 13.2.7. Incyte Corporation
    • 13.2.8. Innovent Biologics, Inc.
    • 13.2.9. Jiangsu Hengrui Medicine Co., Ltd.
    • 13.2.10. Merck & Co., Inc.
    • 13.2.11. Novartis International AG
    • 13.2.12. Pfizer Inc.
    • 13.2.13. Regeneron Pharmaceuticals, Inc.
    • 13.2.14. Sanofi S.A.
    • 13.2.15. Shanghai Junshi Biosciences Co., Ltd.
    • 13.2.16. Tesaro, Inc.
    • 13.2.17. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us